IDEAYA Biosciences Exercises Option to Develop Biocytogen's Potential Cancer Treatment

MT Newswires Live11-11

IDEAYA Biosciences (IDYA) has exercised its option for an exclusive worldwide license for Biocytogen Pharmaceuticals' IDE034 cancer drug as a development candidate, the companies said Monday.

Under agreement between the two companies, Biocytogen will receive fees, regulatory and commercial milestone payments, and royalties totaling $406.5 million.

IDEAYA Science Chief Michael White said the drug candidate "has shown significant tumor regression in preclinical models" in lung, colorectal, and head and neck cancers.

IDEAYA is aiming for an Investigational New Drug submission for the drug to the US Food and Drug Administration in 2025 ahead of possible human trials.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482200491?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-11 19:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482200491","market":"sg","top_or_hot":-1,"title":"IDEAYA Biosciences Exercises Option to Develop Biocytogen's Potential Cancer Treatment","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/IDYA\">IDEAYA Biosciences</a> (IDYA) has exercised its option for an exclusive worldwide license for Biocytogen Pharmaceuticals' IDE034 cancer drug as a development candidate, the companies said Monday.</p><p>Under agreement between the two companies, Biocytogen will receive fees, regulatory and commercial milestone payments, and royalties totaling $406.5 million.</p><p>IDEAYA Science Chief Michael White said the drug candidate \"has shown significant tumor regression in preclinical models\" in lung, colorectal, and head and neck cancers.</p><p>IDEAYA is aiming for an Investigational New Drug submission for the drug to the US Food and Drug Administration in 2025 ahead of possible human trials.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IDEAYA Biosciences Exercises Option to Develop Biocytogen's Potential Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIDEAYA Biosciences Exercises Option to Develop Biocytogen's Potential Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-11 19:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>IDEAYA Biosciences (IDYA) has exercised its option for an exclusive worldwide license for Biocytogen Pharmaceuticals' IDE034 cancer drug as a development candidate, the companies said Monday.Under ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2482200491","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482200491","pubTimestamp":1731326359,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"IDEAYA Biosciences  has exercised its option for an exclusive worldwide license for Biocytogen Pharmaceuticals' IDE034 cancer drug as a development candidate, the companies said Monday.Under agreement between the two companies, Biocytogen will receive fees, regulatory and commercial milestone payments, and royalties totaling $406.5 million.IDEAYA Science Chief Michael White said the drug candidate \"has shown significant tumor regression in preclinical models\" in lung, colorectal, and head and neck cancers.IDEAYA is aiming for an Investigational New Drug submission for the drug to the US Food and Drug Administration in 2025 ahead of possible human trials.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IDYA":"IDEAYA Biosciences"},"translate_title":"IDEAYA Biosciences行使选择权开发百奥赛图潜在的癌症治疗方法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDYA":1},"content_text":"IDEAYA Biosciences (IDYA) has exercised its option for an exclusive worldwide license for Biocytogen Pharmaceuticals' IDE034 cancer drug as a development candidate, the companies said Monday.Under agreement between the two companies, Biocytogen will receive fees, regulatory and commercial milestone payments, and royalties totaling $406.5 million.IDEAYA Science Chief Michael White said the drug candidate \"has shown significant tumor regression in preclinical models\" in lung, colorectal, and head and neck cancers.IDEAYA is aiming for an Investigational New Drug submission for the drug to the US Food and Drug Administration in 2025 ahead of possible human trials.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482200491"}